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The natural product withaferin A (WFA) exhibits
antitumor and antiangiogenesis activity in vivo,
which results from this drug’s potent growth
inhibitory activities. Here, we show that WFA
binds to the intermediate filament (IF) protein,
vimentin, by covalently modifying its cysteine
residue, which is present in the highly con-
served a-helical coiled coil 2B domain. WFA in-
duces vimentin filaments to aggregate in vitro,
an activity manifested in vivo as punctate cyto-
plasmic aggregates that colocalize vimentin
and F-actin. WFA’s potent dominant-negative
effect on F-actin requires vimentin expression
and induces apoptosis. Finally, we show that
WFA-induced inhibition of capillary growth in
a mouse model of corneal neovascularization
is compromised in vimentin-deficient mice.
These findings identify WFA as a chemical
genetic probe of IF functions, and illuminate a
potential molecular target for withanolide-
based therapeutics for treating angioprolifera-
tive and malignant diseases.
INTRODUCTION
In the postgenomic era, natural products are gaining
importance in cell biological applications as molecular
probes of protein function [1], expanding from their more
traditional role as chemical scaffolds for drug develop-
ment. Particularly interesting to molecular medicine are
the pharmacologically active small molecules, the newly
discovered binding targets of which can offer critical mo-
lecular insight into the drugable chemical space of the
human proteome [2]. Such bioactive small-molecule toolsChemistry & Biology 14, 6can also become molecular beacons of target functions,
a feature that has applications in target-based disease
diagnosis and patient responses to drug therapies.
Angiogenesis, which is the growth of new blood vessels
from preexisting vasculature, occurs widely in numerous
human pathologies, including cancers, arthritis, endo-
metriosis, age-related macular degeneration, diabetic
retinopathy, etc. [3]. As new developments in antiangio-
genesis research are providing crucial knowledge of
which protein targets are sensitive to drug treatment,
there is still the increasing need to discover novel drugable
targets [4]. To probe the chemical diversity of plants for
new classes of angiogenesis inhibitors, we recently devel-
oped a high-density, cell-based screening assay, and
focused on the medicinal plant Withania somnifera [5],
because of the elaboration of alkaloids and steroidal lac-
tones (withanolides) present in this plant [6].W. somnifera
has also rich ethnopharmacological uses in traditional
East Indianmedicine for treatment of arthritis, immunolog-
ical disorders, and bleeding conditions in women [7],
which suggested to us the presence of inhibitors that
target an underlying angiogenic mechanism. The rational
screening strategy led to the successful isolation of with-
aferin A (WFA), an inhibitor known for its potent anticancer
activities [8]. We demonstrated that WFA potently blocks
angiogenesis in vivo [5], and investigations on the mode
of action of WFA and structurally related congers has
revealed that this class of withanolides target the
ubiquitin-proteosome pathway (UPP) and cause rapid
increases in polyubiquitinated proteins in vascular endo-
thelial cells [5, 9].
To understand the mode of action of WFA, we exploited
the chemical genetic approach to discover the in vivo
binding targets of small molecules [10, 11]. To this end,
we synthesized a novelWFA-biotin analog, in which the bi-
otin affinity tag was linked to WFA via a long hydrocarbon
chain residue [12], a strategywe and others have employed
extensively to afford the successful characterization of23–634, June 2007 ª2007 Elsevier Ltd All rights reserved 623
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A Binding Target of Withaferin AFigure 1. Affinity Identification of Binding Target of WFA from Endothelial Cells
(A) Chemical structures of WFA and 12-D WS.
(B) Affinity isolation of WFA-B-binding proteins. BAECs were preincubated with DMSO (vehicle) or with 5 mM WFA for 30 min and subsequently
with 5 mM WFA-B for 2 hr. Cell lysates prepared in 1% Triton X-100 buffer were purified over NeutrAvidin affinity columns and subjected to
SDS-PAGE. The gel was stained with Coomassie blue. The arrow points to the 56 kDa protein band and asterisks mark the coeluted 51 and
43 kDa proteins.
(C) WFA-B binds to the 56 kDa protein in HUVECs. Cells were preincubated with DMSO or WFA for 30 min and subsequently with WFA-B for 2 hr.
Soluble proteins extracted in 1% Triton X-100 were fractionated by SDS-PAGE and blotted. Blots were developed with Streptavidin-HRP.
(D) WFA-B binds vimentin in HUVECs. Cell cultures were preincubated with DMSO (vehicle) or with 5 mMWFA or 1 mM for 30 min and subsequently
with 5 mMWFA-B for 2 hr. Cell lysates prepared in 1%Triton X-100 buffer were purified over NeutrAvidin affinity columns and subjected to SDS-PAGE
and western blotted with anti-vimentin V9 antibody. The bottom panel represents streptavidin-HRP detection of endogenous biotinylated species
used as a loading control.
(E) Tetrameric soluble hamster vimentin was incubated with different doses of WFA or inactive congener 12-D WS for 1 hr and subsequently with
0.3 mM WFA-B for 1 hr at 37C. The proteins were fractionated by SDS-PAGE, blotted and probed with vimentin V9 antibody for loading control,
stripped, and reprobed with streptavidin-HRP to detect biotinylated adducts.small-molecule targets [13–16]. Using the novel WFA-
biotin probe, which maintains the UPP-targeting activity
of WFA, we previously showed that a 56 kDa protein is
irreversibly targeted by WFA in human umbilical vein
endothelial cells (HUVECs) [12]. Here, we have isolated
this in vivo binding protein of WFA, and show that it is
the type III intermediate filament (IF) protein vimentin. As
vimentin is abundantly expressed by mesenchymal cells
and plays a critical role in wound healing, angiogenesis,
and cancer growth [17–19], here we demonstrate that
WFA can be used as a chemical genetic probe of vimentin,
identifying the dominant-negative role of WFA-modified
vimentin as a promoter of cellular apoptosis.624 Chemistry & Biology 14, 623–634, June 2007 ª2007 ElsevieRESULTS AND DISCUSSION
WFA Targets the IF Protein Vimentin
To afford the isolation of the WFA (Figure 1A) target, we
performed scale-up ligand binding studies employing
bovine aortic endothelial cells (BAECs). The WFA-biotin
analog (WFA-B; see Figure S1 in the Supplemental Data
available with this article online) was incubated with
BAECs in the presence and absence of unconjugated
WFA, and cell lysates containing newly biotinylated
proteins were affinity-purified over NeutrAvidin columns
and fractionated by sodium dodecylsulfate polyacryl-
amide gel electrophoresis (SDS-PAGE). Gels stained withr Ltd All rights reserved
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A Binding Target of Withaferin ACoomassie blue dye confirmed the isolation of this 56 kDa
protein from BAECs, and revealed that in vivo competition
with unconjugatedWFA dramatically reduced the levels of
this protein (Figure 1B). LC-MS/MS characterization of
this protein identified the 56 kDa protein as vimentin
(27% protein coverage; Figure S2), an IF protein that is
abundant in mesenchymal cells. To further support that
vimentin is bound byWFA-B in vivo, HUVECswere treated
withWFA-B in the presence and absence of unconjugated
WFA, and total cellular lysates were fractionated by SDS-
PAGE and protein blots probed with streptavidin-horse-
radish peroxidase (HRP). We found that the biotin label
is incorporated in this 56 kDa protein in a WFA-competi-
tive manner (Figure 1C). Additionally, when such biotiny-
lated proteins from HUVECs were affinity purified over
NeutrAvidin columns, WFA treatment competed with the
binding of vimentin to the NeutrAvidin column in a dose-
responsive manner, as shown by western blot experi-
ments (Figure 1D). As prior studies have revealed that
the tetrameric form of vimentin is found in vivo and exists
in dynamic equilibrium with filament polymers [20], we
therefore investigated whether WFA binds to purified
tetrameric vimentin in vitro. We performed ligand binding
assays employing unconjugated WFA as a specific com-
petitor and 12-deoxowithastramonolide (12-D WS) as
a nonspecific competitor [12], and show that vimentin is
bound by WFA-B in a WFA-competitive manner (Fig-
ure 1E). Interestingly, theWFA-B-affinity chromatographic
approach has also led to coisolation of two other proteins
of sizes 51 kDa and 43 kDa that were simultaneously
reduced in intensity by WFA treatment in BAECs (Fig-
ure 1B). The characterization of these proteins by LC-
MS/MS revealed that they are 51 kDa b-tubulin and 43
kDa b-actin (Figure S3). Importantly, these NeutrAvidin-
bound proteins, when subjected to 6 M urea treatment,
caused disruption of b-actin and b-tubulin binding,
whereas that of vimentin was not affected (Figure S4),
suggesting that the in vivo binding target of WFA-B is
vimentin. One possibility is that vimentin, through its inter-
action with plakins [21], could bind b-actin and b-tubulin
and provide a cargo for microtubule-dependent protein
transport [22], or it may possibly also bind to b-actin via
direct interaction [23]. In this respect, we previously found
a 180 kDa protein that copurifies with 56 kDa vimentin
upon NeutrAvidin chromatography [12], a species which
is possibly the plakin, bullous pemphigoid antigen 1.
Clearly, the coisolation of vimentin-associated proteins
with WFA-B unveils a novel use for this reagent in chemi-
cal proteomics.
WFA Covalently Modifies the Unique Cysteine
Residue in Tetrameric Vimentin
Next, to identify the amino acid residue(s) of vimentin
modified by WFA, we incubated purified hamster tetra-
meric vimentin with WFA for 1 hr at 37C and subjected
the protein-ligand complexes to tryptic digestion and
LC-MS/MS analysis. A search for the position of adduct
formation (amolecular mass shift of 470) in the tryptic frag-
ments of vimentin revealed that the sole cysteine residueChemistry & Biology 14, 6at position 327 (position 328 in human vimentin) in the
a-helical coil coiled 2B rod domain of vimentin is uniquely
modified by WFA (Figure 2). This finding is consistent with
prior reports that WFA is known to react with protein thiol-
nucleophiles and can undergo Michael addition through
its reactive A-ring (Figure 1A) pharmacophores [24].
Molecular Model of Tetrameric Vimentin Reveals
a Novel WFA-Binding Pocket
We then developed a three-dimensional model of the
WFA-vimentin complex by using X-ray crystal structures
of vimentin [25] andWFA [26]. Molecular modeling studies
revealed a stable binding mode for WFA in the surface
binding pocket of tetrameric vimentin between the pair
of head-to-tail a-helical dimers (Figure 3A). In this simu-
lated model, the C3 and C6 carbons of WFA lie in close
proximity to the cysteine residue in the vimentin A helix
(Figure 3B), permitting a nucleophilic attack by this thiol
group on the electrophilic carbon centers (Figure 3C). Re-
markably, the amino acid residues of vimentin (Gln324,
Cys328, and Asp 331) that make contact with WFA
(Figure 3C) are identical from mammals down to ancient
fish, such as sharks [27] (Figure S5). Another feature illus-
trated by this model is that the orientation of C27 hydroxyl
group places thismoiety outside the binding cleft; thus, bi-
otinylated WFA (Figure S1) is able to retain the flexibility to
bind immobilized NeutrAvidin after modifying tetrameric
vimentin in vivo. On the other hand, the simulated model
of vimentin/the inactive congener 12-D WS (Figure 3D)
reveals that the C5 alpha-hydroxyl and the C6-C7 epoxide
of WFA are positioned to prevent rear side nucleophilic
attack by the reactive thiol group on 12-D WS. This dis-
tinction between these two withanolides in their binding
modes with vimentin is further corroborated by comparing
the molecular docking-simulated internuclear distances
between WFA and 12-D WS with vimentin (Figure S6),
and these data are consistent with lack of in vitro binding
activity of 12-D WS to vimentin (Figure 1D).
Covalent Modification of Tetrameric Vimentin by
WFA Causes Formation of Filament Aggregates
In Vitro and In Vivo
The clinical importance of the cysteine residue in vimentin
lies in its propensity for being preferentially oxidized in
vimentin compared to other cytoskeletal proteins from
rheumatoid arthritis patients [28]. Because this cysteine
residue under oxidizing conditions can participate in disul-
fide cross-linking between a pair of vimentin dimers, lead-
ing to disruption to the filament structure in vitro [29], we
next investigated how chemical modification of cysteine
by WFA affects the vimentin IF structure. Employing solu-
ble tetrameric vimentin in filament polymerization assays
in vitro, we show that, although WFA at high doses does
not block filament assembly per se, the drug induces for-
mation of filamentous aggregates, many of which display
amorphous condensed structures, as revealed in nega-
tively stained transmission electron micrographs (Fig-
ure 4). This phenotype is not observed with lower doses
of WFA or equivalent high doses of the inactive congener,23–634, June 2007 ª2007 Elsevier Ltd All rights reserved 625
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A Binding Target of Withaferin AFigure 2. WFA Modifies the Unique Cysteine Residue of Vimentin
Tetrameric vimentin was incubated withWFA or DMSO and small molecule-protein complexwas subjected to trypsin digestion. The tryptic fragments
were subjected to LC-MS/MS analysis. The assignment of fragment ions in the MS/MS of the modified and unmodified peptides were obtained with
the SEQUEST software tool ‘‘FuzzyIons’’ (distributed by ThermoFinnigan) to annotate the spectra (A) fromWFA-treated sample and (B) from DMSO-
treated sample. This analysis verifies both the peptide amino acid sequence and the location andmass of themodification (+470Daltons on cysteine).626 Chemistry & Biology 14, 623–634, June 2007 ª2007 Elsevier Ltd All rights reserved
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A Binding Target of Withaferin AFigure 3. Molecular Model of WFA Binding Site in Tetrameric Vimentin
Molecularmodeling of theWFA binding site in the vimentin tetramer model was derived with the crystal structures of the protein fragments associated
with the PDB accession code 1gk4. Based on this model, MD-simulated annealing was performed to dock WFA to the vimentin tetramer fragment.
The final protein-ligand binding structure was based onMD simulation (with the AMBER 8 program) in a water bath for 1.7 ns. The binding structure is
stable in water. Images of the models were generated with PyMol software.
(A) Depicted in the figure is a snapshot of the MD-simulated solvent-accessible surface area binding structure showing WFA binding in the cleft be-
tween the A and A0 a helices of the vimentin tetramer.
(B) The close-up image shows the A-ring twist-boat and B-ring half-chair conformation of WFA [26] (see Figure 1A) is accommodated deep within the
binding cleft of the vimentin tetramer, allowing for proper orientation with Cys328 (yellow) to form a covalent bond with the C3 or C6 electrophilic
carbon centers of WFA. Note that the exocyclic C27 hydroxyl group (arrow) of WFA to which the linker-biotin was conjugated is orientated toward
the solvent-side of the binding cleft that makes it possible for WFA-B to bind tetrameric vimentin.
(C) The model shows hydrogen bonding between Gln324 of the vimentin A-helix and the C1 position oxygen atom (2.3 A˚), and Asp331 of the vimentin
A0 helix and the C4 hydroxyl group (1.7 A˚).
(D) The alpha orientations of the C5 (OH) and C6-C7 (epoxide) of the inactive withanolide congener 12-D WS appose Cys328 of vimentin, thus
preventing nucleophilic attack by the thiol group on the electrophilic carbon centers.12-D WS. To further corroborate that vimentin aggrega-
tion by WFA treatment is associated with perturbation of
the cytoskeleton structure, we investigated drug effects
in BAECs by immunostaining. Cells treated with 3 mM
WFA showed condensation of vimentin filaments around
the perinuclear region and the presence of numerous,
vimentin-positive staining particles in the cytoplasm (Fig-
ure 4; compare Figures 4E and 4F). Importantly, these
vimentin particulates strongly costain for actin (Figure 4;
compare Figures 4H and 4J), exemplifying the role of theChemistry & Biology 14, 62WFA-binding domain in control of cytoskeletal structure
through actin-perturbing activity of vimentin [21–23].
WFA Causes Vimentin Fragmentation In Vivo
As it became apparent that vimentin targeting by WFA
may initiate signaling events leading to cellular apoptosis,
we wanted to know whether soluble tetrameric vimentin,
which is difficult to differentiate from the abundant fila-
ments by staining, is also affected byWFA. Through west-
ern blot analysis of soluble proteins from HUVECs treated3–634, June 2007 ª2007 Elsevier Ltd All rights reserved 627
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A Binding Target of Withaferin AFigure 4. WFA Causes Aggregation of Vimentin Filaments
In Vitro and In Vivo
(A) Tetrameric soluble hamster vimentin was polymerized in presence
of 170 mM NaCl by incubation at 37C for 1 hr. The protein was fixed
with 0.5% glutaraldehyde, stained with uranyl acetate, and observed
by transmission EM. The presence of vehicle solvent does not interfere
with filament formation. (B) Polymerization of tetrameric vimentin in the
presence of 25 mM WFA produces extensive filamentous aggregates
and (C) many irregular fragmented aggregated structures. (D) 12-D
WS (25 mM) does not disrupt vimentin polymerization. BAECs treated
with DMSO (E, G, I) or 3 mM WFA (F, H, J) for 18 hr were stained for
vimentin with a monoclonal anti-vimentin antibody (green) and cos-
tained with phalloidin-rhodamine (red). The vimentin (E) and (F) and628 Chemistry & Biology 14, 623–634, June 2007 ª2007 Elseviewith WFA, we show dose-dependent (above 2 mM) in-
creases in vimentin cleavage products (Figure 5A), which
became more pronounced by 2 hr, paralleling the
decreased expression of the 56 kDa form after drug treat-
ment (Figure 5B). Since several posttranslationally modi-
fied isoforms of vimentin exist in cells, we performed
two-dimensional western blot analysis to better charac-
terize the vimentin-targeting activity ofWFA. As compared
with the vehicle-treated cells (Figures 5C and 5D), WFA
treatment was found to cause reductions in the levels of
several 53–56 kDa isoforms (Figure 5E), with WFA-B
treatment also inducing similar reduction in levels of
vimentin isoforms at cyctotoxic doses of this WFA analog
(Figure 5F). These data further support the in vivo drug-
mimetic effect of WFA-B.
The Ubiquitin-Proteasome Pathway-Targeting
Activity of WFA is Mediated by Vimentin
Since IF protein aggregation has been shown to negatively
impact the UPP, resulting in proteasome inhibition [30], we
queried whether the UPP-targeting activity of WFA [5, 9] is
also regulated in a vimentin-dependent manner. Employ-
ing the widely used MCF-7 vimentin-deficient cell culture
model [31], we found that WFA causes increased levels
of polyubiquitinated proteins in vimentin-transfected
MCF-7 cells, but only moderately in the vector controls
(Figure 6A). We addressed the importance of the 2-3 un-
saturated position of the A-ring on UPP activity of WFA
by structure-activity relationship studies. We found that
the semisynthetic analogs, 3b-methoxy-dihydrowithaferin
A or 3b-thiophenoxy-dihydrowithaferin A, like the inactive
congener, 12-D WS [12], also failed to increase cellular
levels of ubiquitinated species (Figure S7A). Similarly,
vimentin-transfected MCF-7 cells treated with 12-D WS
also failed to increase levels of ubiquitinated proteins
(Figure S7B). These results are consistent with the binding
mode of WFA for vimentin (Figure 3). Next, to corroborate
that vimentin targeting, and not the possible direct inhibi-
tion of the 20S proteasome byWFA, mediates its UPP-tar-
geting function [9], we tested WFA in proteasome kinetic
assays. We show that, whereas the highly selective 20S
proteasome inhibitor, epoxomicin [13], significantly in-
hibits the 20S proteasome’s major catalytic function at
10 nM, WFA minimally inhibits this catalytic activity,
even at cytotoxic concentrations of 10 mM (Figure 6B).
The Kobs/[I] (M
1S1), a measure of the efficiency of inac-
tivation [13], was calculated to be 340 ± 80 (0.5–10 mM) for
WFA, while that of epoxomicin is 44,510 ± 7,000 (10–75
nM). Contrary to a recent report [32], our data suggest
that WFA-modified vimentin may mediate sequestration
of ubiquitinated proteins and result in proteasome inhibi-
tion in vivo. Thus, employing cell lines derived from vimen-
tin-deficient and isogenic wild-typemouse strains [33], we
phalloidin-stained images (G) and (H) in fluorescence overlap reveal
the presence of numerous cytoplasmic particulate granules that cos-
tain for vimentin and disrupted F-actin in WFA-treated cells compared
to controls (I) and (J).r Ltd All rights reserved
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A Binding Target of Withaferin AFigure 5. WFA Induces Vimentin Fragmentation in Endothe-
lial Cells
(A) Western blot analysis of HUVECs shows dose-responsive in-
creases in vimentin cleavage products (arrows) withWFA treatment af-
ter 2 hr as detected with the monoclonal anti-vimentin V9 antibody.
(B) Higher concentrations and longer periods of exposure toWFA (4 hr)
cause reduction in levels of the 56 kDa protein (asterisk) and increased
abundance of cleavage products of vimentin (arrows).
(C) Two-dimensional western blotting analysis of WFA-treated HU-
VECs. Cells were extracted with buffer A and soluble lysates were sub-
jected to isoelectric focusing with IPG strips (Biorad). The second di-
mension was performed with 4%–20% polyacrylamide gels and
proteins transferred on membranes for western blot analysis. Protein
blots were probed with anti-vimentin monoclonal antibody (V9). IPG
strips in the range of pH 4–7 were employed to allow for fine resolution
of closely migrating vimentin isoforms.
(D–F) Expanded images (range, pH 4–6) of western blots from control
(D), WFA- (E), and WFA-B-treated (F) HUVECs show the dramatic re-
duction in spot intensity of many vimentin isoforms in drug-treated
cells.Chemistry & Biology 14, 62show that vimentin deficiency confers enhanced resis-
tance to WFA-induced apoptosis with wild-type cells hav-
ing a 7-fold higher rate of apoptosis, whereas 12-D WS
does not induce apoptosis in wild-type cells (Figure 6C).
Furthermore, exploiting a protein transduction methodol-
ogy to introduce the WFA-modified, dominant-negative
vimentin tetramers into cells, we found by immunostaining
that endogenous vimentin IFs and F-actin are found to
aggregate, whereas cells transduced with vehicle-treated
vimentin do not produce this phenotype (Figure 6; com-
pare Figures 6D and 6F). Thus, vimentin targeting by
WFA has a dominant-negative affect on the cystosketon
architecture, as seen by staining for F-actin (Figures 6E
and 6G). Collectively, these findings identify a potent cyto-
skeleton-perturbing activity of WFA, which is mediated
by vimentin.
The In Vivo Antiangiogenic Activity of WFA
is Mediated by Vimentin
We previously reported that WFA exhibits potent angio-
genesis inhibitory activity in vivo [5]. Thus, here we have in-
vestigated whether the pharmacological activity of WFA
on de novo capillary growth is altered by vimentin defi-
ciency. Through the use of the mouse model of injury-
induced corneal neovascularization, we found that WFA
markedly suppressed neovascularization in wild-type
mice (73% inhibition; n = 8; p = 0.002), whereas it only
marginally attenuated neovascularization in vimentin-null
mice (29% inhibition; n = 10; p = 0.005) (Figure 7), reveal-
ing that inhibition of capillary growth byWFA is largely me-
diated by vimentin. It is likely that vimentin in corneoscleral
capillaries and fibroblastic cells of the injured corneal
stroma [34] is targeted byWFA in this angiogenesismodel.
Furthermore, in accord with our in vitro studies, we find
that the inactive congener, 12-D WS, does not alter cor-
neal neovascularization in wild-type Svev mice (<1% acti-
vation; n = 6; p = 0.1724). Interestingly, the vascularization
response of vimentin-deficient mice is not as extensive as
in wild-type mice, which is consistent with previous re-
ports on impaired angiogenesis in vimentin deficiency
[19] and the likely impairment of vimentin-dependent me-
chanosignaling events in the vasculature [35].
WFA has recently been reported to bind annexin II
in cancer cell lines [36]. However, this 36 kDa protein is
not detected in affinity-purified proteins from bovine
(Figure 1B) or human (Figure 1C) [12] endothelial cells,
nor was it detected by western blotting of NeutrAvidin-
purified proteins in our studies (data not shown). Thus,
we are drawn to the interpretation that differences in the
construction of the biotinylated WFA analogs (e.g., inclu-
sion of a long, linear hydrocarbon linker between the natu-
ral product and biotin) [10, 37] or their applications for tar-
get isolation (in vitro versus in vivo labeling) could account
for different targets being bound toWFA. It is also possible
that WFA has binding specificities for different targets
in vivo, which may also be context related. Since vimentin
deficiency does not abrogate WFA’s biological activities
totally, the existence of other relevant targets of this com-
poundmust be considered. The related IF protein, desmin,3–634, June 2007 ª2007 Elsevier Ltd All rights reserved 629
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A Binding Target of Withaferin AFigure 6. WFA-Induced Upregulation of
Protein Ubiquitination is Mediated by Vi-
mentin
(A)MCF-7 cells that lackendogenous IF proteins
were transfected with human vimentin cDNA
or a vector control and, after 24 hr, cells were
treated with either vehicle or 2 mMWFA for 1 hr.
Cell lysates were prepared and equal amounts
of protein subjected to SDS-PAGE and protein
blots probed with anti-ubiquitin antibody. Blots
were reprobed with anti-GAPDH antibody.
(B) 20S proteasome (bovine) preparation was
incubated with vehicle (control), 0.5 mM, 1.0 mM
and 10 mM WFA or with 10 nM Epoxomicin
(Epx) in presence of LLVY-AMC substrate at
room temperature. Fluorescence readings from
triplicate samples were obtained at different
time intervals from the 96-well plate with excita-
tion at 355 nm and emission at 430 nm. The re-
lease of product was plotted against time for
each concentration of inhibitor.
(C) Embryonic fibroblast cell lines derived from
vimentin-deficient mice and wild-type litter-
mates [33] were treated with vehicle, 5 mM
WFA, or 5 mM12-DWS for 24 hr. Cells were har-
vestedandstainedwithannexinV-FITCandpro-
pidium iodide, and extent of apoptosis assessed
by flow cytometry. The fold-apoptosis for drug
over vehicle-treated samples for each cell line
wasplotted (n=2 experiments); errorbars repre-
sent SD.
(D) BAECs were transduced with WFA-modified
vimentin and cells were stained after 18 hr.
(E) Cells transducedwithWFA-modified vimentin showboth condensed vimentin filaments localized largely in and around the nucleus and thepresenceof
vimentin-staining particulates.
(F and G) Cells transduced with vehicle-treated vimentin showwell-distributed orchestration of vimentin IFs (F) and actin cytoskeleton (G). Results repre-
sentative of three experiments are shown.could be a relevant target, because theWFA-bindingmotif
is conserved in desmin (Figure S5) [27]. Thus, the modest
WFA inhibitory activity on corneal neovascularization
in vimentin-deficient mice may be due to the targeting of
desmin in mural cells of invasive capillaries [34]. While
this theory remains to be tested, our findings underscore
the importance ofmultiple target activity ofWFA that could
be exploited for drug development.
In conclusion, this study illustrates the cell biological and
pharmacological use of a small molecule that targets type
III IF proteins via modification of the conserved rod 2B
domain. Intriguingly, a recent report has shown that the
antiangiogenic and chemopreventive agent, epigallocate-
chin gallate, also binds to vimentin, although via the N-
terminal region of this protein [38]. The revelation that
vimentin is a critical target of such chemically diverse nat-
ural products (withanolides and flavanoids) provides new
opportunities to investigate potential synergistic effects
of these inhibitors on cell signaling networks evoked under
malignant, angiofibrotic, and inflammatory conditions [39].
SIGNIFICANCE
Withaferin A (WFA) is a prototype of the withanolide
class of natural products that exhibit diverse pharma-630 Chemistry & Biology 14, 623–634, June 2007 ª2007 Elsevcological activities, including antitumor, antiangio-
genic, cardioprotective, anti-inflammatory, and immu-
nomodulatory effects [7]. Our findings showing that
site-specific modification of vimentin by WFA in vivo
causes endothelial cell apoptosis illuminates the
chemical genetic approach of perturbing the con-
served rod 2Bdomain to produce a dominant-negative
effect on intermediate filament (IF) protein function.
Use of such a small molecule to alter IF function can
serve as a complementary approach to classical ge-
netic studies of disorders of IFs [40], and, potentially,
WFA-B can also be exploited as a chemical proteomic
reagent for investigating the IF proteome. Thus, WFA
and derivative steroidal lactones represent a class of
useful chemical genetic tools for studies of the type
III IF proteins. As vimentin modulates the immune re-
sponse [41], and is overexpressed in prostate and
other cancers [42], WFA holds great promise as a po-
tential drug lead for the development of small-mole-
cule therapeutics.
EXPERIMENTAL PROCEDURES
All cell culture supplies were purchased fromGIBCO, unless otherwise
specified. Antibodies were from Santa Cruz Biotechnology, unless
otherwise specified. WFA and 12-D WS were obtained fromier Ltd All rights reserved
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A Binding Target of Withaferin AFigure 7. Vimentin Mediates the Antian-
giogenic Activity of WFA
Wild-type mice and vimentin-deficient mice
were subjected to corneal chemical injury
with limbal and corneal epithelial cell debride-
ment. Mice were treated by daily intraperi-
teoneal injection with vehicle, 2 mg/kg WFA,
or 2 mg/kg 12-D WS for 10 days. Neovascula-
rization responses in corneas were assessed
by flat-mount staining with anti-CD31-floures-
cent antibodies.
(A) Flat-mount stained corneas were photo-
graphed and representative images of CD31+
(fluorescent) capillaries are shown.
(B) Quantification of neovascularization from
each group of mice (n = 14, Vim+/+; n = 10,
Vim/) was performed as previously de-
scribed [45]. Error bars represent SD; * p <
0.05 by Mann-Whitney U test.Chromadex, and stock solutions were freshly prepared in DMSO. The
synthesis of WFA analogs, 3b-methoxy-dihydrowithaferin A and 3b-
thiophenoxy-dihydrowithaferin A, is described in Supplemental Exper-
imental Procedures provided in the Supplemental Data. All cell re-
agents were purchased from Invitrogen.
Cell Cultures and Reagents
HUVECs and BAECswere obtained fromCascade Biologicals and cul-
tured according to the vendor’s protocols. The MCF-7 breast cancer
cell line was obtained from American Type Culture Collection and cul-
tured in RPMI 1640 medium containing 10% fetal bovine serum (FBS).
MFT-16 cells from embryo fibroblasts of vimentin homozygous-
deficient mice (Vim/) and MFT-6 cells from embryo fibroblasts of
wild-type (Vim+/+) mice were obtained from Robert Evans (University
of Colorado, Denver, CO) and cultured in F12:DMEM (1:1) medium
supplemented with 5% FBS. All cells were cultured in humidified incu-
bators at 37C-5% CO2 conditions.
Isolation of WFA-B-Binding Proteins by Affinity
Chromatography
The synthesis and chemical characterization of WFA-B and its use to
identify biotinylated proteins from HUVECs was previously reported
[12]. For scale-up studies, BAECs were preincubated with DMSO or
5 mM WFA for 1 hr and subsequently treated with 5 mM WFA-B for
2 hr. Cells were washed in ice-cold phosphate-buffered saline (PBS)
and cytoplasmic extracts were prepared in buffer A (5 mM Tris, pH
7.6, 50 mM NaF, 1% Triton X-100, 5 mM EGTA) supplemented with
a proteinase inhibitor cocktail (Roche). After centrifugation, equalChemistry & Biology 14, 6amounts of protein were precleared on agarose beads (Sigma) to re-
move nonspecific agarose-binding proteins. The beads were centri-
fuged and precleared cell lysates were repeatedly loaded three times
on columns containing NeutrAvidin-agarose beads (Pierce) to maxi-
mize immobilization of biotinylated proteins. After extensive washing
with ice-cold buffer A, bound biotinylated proteins were eluted in Lae-
meli gel loading buffer containing b-mercaptoethanol, and fractioned
by SDS-PAGE on 153 15 cm gels. Gels were stained with Coomassie
blue dye, and bands corresponding to 56 kDa, 51 kDa, and 43 kDa
protein were excised for mass spectrometric analysis.
Identification of Affinity-Purified Proteins by LC-MS/MS
All mass spectra reported in this study were acquired by the University
of Kentucky Mass Spectrometry Facility. Gel pieces were digested
with trypsin, and LC-MS/MS spectra were acquired on a ThermoFinni-
gan LCQ ‘‘Classic’’ quadrupole ion trap mass spectrometer (Finnigan
Co., San Jose, CA). Separations were performed with an HP 1100
high-performance liquid chromatograph modified with a custom split-
ter to deliver 4 ml/min to a custom C18 capillary column (300 mm inner
diameter3 15 cm). Gradient separations consisted of a 2min isocratic
step at 95% water and 5% acetonitrile (both phases containing 0.1%
formic acid). The organic phasewas increased to 20%acetonitrile over
8 min, and then increased to 90% acetonitrile over 25min, held at 90%
acetonitrile for 8 min, and then increased to 95% in 2 min; finally, they
were returned to the initial conditions in 10 min (total acquisition time,
45 min with a 10 min recycle time). Tandem mass spectra were ac-
quired in a data-dependent manner. Three microscans were averaged
to generate the data-dependent full-scan spectrum. The most intense23–634, June 2007 ª2007 Elsevier Ltd All rights reserved 631
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scans were averaged to produce the MS/MS spectrum. Masses
subjected to the MS/MS scan were placed on an exclusion list for
2 min. Resulting MS/MS spectra were searched against mammalian
proteins in the Swiss-Prot database with the Mascot search engine
(Matrix Science).
WFA Binding Site Identification in Vimentin
Hamster tetrameric vimentin (0.5 mg/ml) was incubated with 10 mM
WFA or an equivalent amount of DMSO for 1 hr at 37C. Protein-ligand
complexes were subjected to tryptic digestion and LC-MS/MS analy-
sis. The assignment of fragment ions in theMS/MS of the modified and
unmodified peptides was obtained with the SEQUEST software tool
‘‘FuzzyIons’’ (distributed by ThermoFinnigan) to annotate the spectra
from WFA-treated and DMSO-treated samples. This analysis verifies
both the peptide amino acid sequence and the location and mass of
the modification (+470 daltons on cysteine).
3D Model of the Human Vimentin Fragment
The initial coordinates of 2B human vimentin fragment used in our
computational studies came from the X-ray crystal structure (Protein
Data Bank [PDB] code: 1gk4) [25] deposited in the PDB. To encom-
pass the structure of the protein environment surrounding the active
residue Cys328, the missing residues of the 2A fragment (i.e., residues
313–327 in A andB helices) were built with the a-helical template struc-
ture and the automated homology modeling tool, Modeler/InsightII
software (Accelrys, Inc.). Then, the best 3D model was solvated in
water and refined by performing a long-time molecular dynamics
(MD) simulation in water (see Supplemental Experimental Procedures).
Molecular Docking
To explore the possible vimentin-ligand binding mode, the first step
was to dock the ligand (i.e., WFA) or 12-D WS to vimentin tetramer
fragment by virtue of their geometric complementarity. We aimed to
find where the ligand could be inserted most comfortably. The molec-
ular docking for each vimentin-ligand binding was carried out in the
same way as we recently did for studying other protein-ligand binding
systems [43]. Briefly, a ligand-binding site was defined as that consist-
ing of the residues within a sphere (with a radius of 20 A˚) centered at
Cys328 residue. The ligand was initially positioned at 10 A˚ in front
of Cys328 of the binding site. The initial docking calculations were per-
formed on the ligand with the vimentin fragment binding site by the
‘‘automatic docking’’ Affinitymodule of the InsightII package (Accelrys,
Inc.). The Affinity methodology uses a combination of Monte Carlo-
type and simulated annealing procedures to dock the guest molecule
(the ligand) to the host (the receptor). The vimentin-ligand binding
structure obtained from the initial docking was further refined by
performing an MD simulation in a water bath (see Supplemental Ex-
perimental Procedures).
Western Blotting Experiments
After treatments, cells were washed in PBS and extracts having equal
amount of proteins were subjected to SDS-PAGE on 4%–20% Tris-
glycine gels (BioEpress) and transferred to Immun-Blot PVDF mem-
brane (Bio-Rad) by standard techniques. Primary antibodies were
diluted in 5% nonfat dry milk Tris-buffered saline, 0.02% Tween-20
(NFDM-TBST) at the concentration of 1:500, and secondary antibodies
were used at 1:1000 dilution. Blots were extensively washed in TBST
buffer and developed by enhanced chemiluminescence method
(Amersham) and exposed to X-ray film.
Analysis of Vimentin Isoforms by 2D Gel Electrophoresis
HUVECs cultured in 60 mm dishes were treated with vehicle or 5 mM
WFA or 20 mM WFA-B for 2 hr. Cells were washed in ice-cold PBS
and collected in buffer A. After centrifugation at 14,0003 g for 10 min,
equal amounts of protein from supernatants were suspended in 8 M
urea, 50 mM dithiothreitol (DTT), and 0.2% Bio-lite ampholytes pH
3–5 and pH 5–8 (2:1 ratio; Biorad) with 0.01% bromophenol blue.632 Chemistry & Biology 14, 623–634, June 2007 ª2007 ElsevThe protein lysate was centrifuged at 14,000 3 g for 5 min to precipi-
tate insoluble material before incubationwith 11 cm IPG strips (pH 4–7;
Biorad). Gels were actively rehydrated at 50mA for 12 hr with a Protean
IEF cell system (Biorad). Isoelectric focusing was subsequently con-
ducted for 5.5 hr (250 V for 20 min, 8,000 V for 2.5 hr, and 8,000 V
for 25,000 V hr). Strips were dipped in equilibration buffer 1 containing
6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20% glycerol, and 2%
(w/v) DTT for 10 min, followed by an incubation in equilibration buffer
2 containing 6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20% glyc-
erol, and 2.5% (w/v) iodoacetamide for 10 min. Strips were laid on
second dimension 4%–20% gradient gels (Biorad) and run at 200 V for
1 hr. Proteins were transferred at 100 V for 45 min for western blotting.
Transfection Studies
MCF-7 cells were transfected with a pCMV6-XL5 vector containing the
human vimentin cDNA under CMV promoter, according to vendor in-
structions (Origene). Control samples were transfected with an empty
vector (PCMV6-XL4). Transfected cells were allowed to recover for
12 hr and subsequently treated with vehicle or 2 mMWFA or 12-D WS
for 18 hr. An equal amount of protein lysateswere subjected towestern
blotting and probed with an antiubiquitin mouse monoclonal antibody.
Protein Transduction Studies
Tetrameric vimentin (0.5 mg) (Cytoskeleton) was incubated with 10 mM
WFAor an equivalent amount of vehicle (DMSO) for 1 hr at 37C to form
protein-WFA adducts. Vimentin-WFA or vimentin alone (0.5 mg) was
mixed with the Chariot protein transduction reagent (Active Motif)
and incubated for 30 min at 24C to form complex according to the
manufacturer’s instructions. The protein-Chariot complex was subse-
quently added to BAECs in serum-free medium and incubated for 1 hr
in 37C-5% CO2 conditions. Fresh complete medium was then added
and cells were incubated for an additional 18 hr under normal culture
condition. Cells were processed for immunohistochemistry analysis
as described previously here.
Apoptosis by Flow Cytometry
To assess the apoptosis activity of WFA and 12-D WS, embryonic
fibroblast vimentin-deficient cell lines (Vim/; MFT-16) and wild-
type (Vim+/+; MFT-6) cells [32] were treated with 5 mM WFA, 5 mM
12-D WS, or an equivalent amount of vehicle (DMSO) for 24 hr in
37C-5% CO2 conditions in complete medium. Apoptotic cells were
measured with the Vybrant Apoptosis Assay Kit (Molecular Probes)
according to the manufacturer’s instructions. Flow cytometric analysis
was conducted at the University of Kentucky Core Flow Cytometry
Center.
Cell Staining Procedures and Fluorescence Imaging
After treatments, BAECs were washed with PBS and fixed with 4%
paraformaldehyde for 5 min. Cells were permeabilized with 0.1%
Triton-X in PBS for 20 min at 4C and blocked for 30 min in 3% BSA.
Rabbit polyclonal vimentin antibody (Vim) or mouse monoclonal
vimentin antibody (V9) was applied to cells for 1 hr at 24C at 1:400
dilution in PBS. After washing with PBS, cells were incubated with
anti-rabbit FITC-conjugated secondary antibody (1:500) or anti-mouse
Texas Red-conjugated secondary antibody (1:500) for 30 min. Cells
were washed, and those labeled with Vim-antibody were incubated
with phalloidin-Rhodamine (1:200) for 20 min. After washes for 2 hr,
staining was visualized with a Nikon TE2000 microscope.
Transmission Electron Microscopy of Vimentin Filaments
Tetrameric hamster vimentin was subjected to in vitro filament forma-
tion assays with vendor-supplied reagents and instructions (Vimentin
Filament Biochemistry Kit, Denver, CO). Vimentin (0.5 mg/ml) was
mixed with WFA (5 or 25 mM), DMSO, or 12D-WS (25 mM) in filament
polymerization buffer (170mMNaCl final concentration) and incubated
for 1 hr at 37C. Protein was immediately fixed in 0.5% glutaraldehyde,
stained with uranyl acetate, and applied to copper grids for EM stain-
ing (University of Kentucky Core Microscopy and Imaging Facilities).ier Ltd All rights reserved
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Biotwin 12 transmission electron microscope, and 25 representative
images were collected. The entire experiment was then repeated.
Enzyme Kinetic Studies
KA values were determined as follows. Inhibitors were mixed with a flu-
orogenic peptide substrate and assay buffer (20 mM Tris [pH 8.0], 0.5
mM EDTA, and 0.035% SDS) in a 96-well plate. The chymotrypsin-like
activity was assayed with the fluorogenic peptide substrates, Suc-
Leu-Leu-Val-Tyr-AMC (Sigma-Aldrich). Hydrolysis was initiated by
the addition of bovine 20S proteasome, and the reaction was followed
by fluorescence (360 nm excitation/460 nm detection) with a Micro-
plate Fluorescence Reader (FL600; Bio-Tek Instruments, Inc., Win-
noski, VT) employing the software KC4 v.2.5 (Bio-Tek Instruments,
Inc.). Reactions were allowed to proceed for 60–90 min, and fluores-
cence data were collected every 1 min. Fluorescence was quantified
as arbitrary units, and progression curves were plotted for each reac-
tion as a function of time. Kobs/[I] values were obtained with the PRISM
program by nonlinear least-squares fit of the data to the following
equation: fluorescence = vst + ([v0  vs]/Kobs)(1 – exp[Kobs t]), where
v0 and vs are the initial and final velocities, respectively, and Kobs is the
reaction rate constant. The range of inhibitor concentrations tested
was chosen so that several half-lives could be observed during the
course of the measurement. Reactions were performed with inhibitor
concentrations that were < 100-fold of those of the proteasome
assayed.
Corneal Neovascularization Assays in Mouse
All animal experiments were conducted in accordance with the Decla-
ration of Helsinki, and procedures approved by IACUC committee of
the University of Kentucky. Mice were housed in specific pathogen-
free cages in designated lab animal housing facilities. Vimentin homo-
zygous-deficient mice (Vim/) and mice that were vimentin-heterozy-
gous deficient (Vim+/) in the 129/Svev background were obtained
from David Markovitz (University of Michigan Medical Center) and
breeding colonies established at the University of Kentucky. Age-
matched littermates were genotyped by polymerase chain reaction,
as previously described [44], and Vim/ and Vim+/+ mice were
employed for corneal vascularization experiments [45]. In brief, mice
between 4 and 6 wk of age were anesthetized by intraperiteoneal
(i.p.) injection of ketamine and xylazine. Corneas were topically anes-
thetized by application of proparacain eye drop, and 1 ml drop of dilute
0.15 M sodium hydroxide was applied for 1 min. The cornea was
immediately washed extensively in saline solution, and corneal and
limbal epithelium gently removed by scraping with a blunt Tooke cor-
neal knife. The cornea was topically treated with atropine eye drop and
covered with tobramycin and erythromycin antibiotic eye ointment.
WFA or 12-D WS (2 mg/kg solubilized in DMSO) or vehicle (DMSO)
was injected i.p. in respective drug or control groups of mice after their
recovery from corneal injury, and subsequently every day thereafter for
a period of 10 days. Mice were humanely killed and eyes enucleated.
The anterior segment half of eyes were dissected and corneal buttons
were prepared. Corneal tissues were fixed in 100% acetone for 20min,
washed in PBS for 1 hr, and blocked for 18 hr in 1% BSA-PBS at 4C.
Cornea whole-mount staining was performed by incubating tissues in
FITC-conjugated rat anti-mouse CD31 antibody (BD PharMingen;
1:333 dilution in 1% BSA-PBS) for 12 hr, washed away for 24 hr at
4C in 1% BSA-PBS, and affixed to glass slides with a coverslip. Fluo-
rescent staining was visualized on a Nikon TE2000 microscope, and
quantified by importing digital images to NIH ImageJ [45].
Supplemental Data
Supplemental Data, including Supplemental Experimental Procedures
used in this work, Supplemental References, and seven figures are
available online at http://www.chembiol.com/cgi/content/full/14/6/
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